Authors
  • Dr. Robert Motzer is a board-certified medical oncologist who is dedicated to improving the lives of patients with genitourinary tumors. Dr. Motzer’s primary area of expertise is in renal cell carcinoma and germ-cell tumors. For more than 25 years, Dr. Motzer has used his skills as a clinician to provide high-quality and compassionate care for cancer patients at Memorial Sloan Kettering Cancer Center in New York, NY. In addition to providing patients with the highest standard of medical care, Dr. Motzer has led more than 50 clinical trials in patients with kidney cancer and testicular cancer, including national and international multicenter clinical trials. His research has helped to identify five targeted drugs — sunitinib (Sutent®), pazopanib (Votrient®), axitinib (Inlyta®), temsirolimus (Torisel®), and everolimus (Afinitor®) — as effective treatments for patients with advanced kidney cancer. Also, he developed a system to aid in the prediction of treatment outcomes for patients taking medications for advanced kidney cancer; this (“MSK”) risk system is widely applied by physicians internationally to direct the care of patients. In the area of testicular cancer, his patient care and research efforts focus on developing better treatments for patients with difficult-to-treat tumors. On both a national and international level, Dr. Motzer has worked to improve the quality and delivery of cancer care for individuals diagnosed with kidney cancer and testicular cancer. He chairs the National Comprehensive Care Network Kidney Cancer and Testicular Cancer Guidelines Panel. He has published more than 400 original articles, scientific reviews, chapters and abstracts. Dr. Motzer is a recipient of the Career Development Award from the National Institutes of Health; the Willet F. Whitmore Award for Clinical Excellence from Memorial Sloan Kettering; and the Schonfeld Award from the Kidney Cancer Association, a charitable organization dedicated to kidney cancer patient advocacy.
    • Cardiovascular Disease
    • Lead, Immunotherapy Unit at Gustave Roussy Institute
    Dr Escudier is a MD, trained in Paris. He got his MD in 1981 as a cardiologist, and moved to Gustave Roussy Institute in 1983, initially in the Intensive Care Unit, and then took the lead of the Immunotherapy Unit, mainly in charge of developing programs in renal cell carcinoma and in melanoma. His largest fields of interest are renal cell carcinoma, immunotherapy (cytokines, vaccine), and development of new strategies (antiangiogenic drugs, gene therapy). He has been largely involved in the development of new targeted therapies for RCC, and has been the PI of many trials in the field of RCC, from phase I to phase III. Dr Escudier is the head of the French Group of Immunotherapy since 1992, and the chairman of the GU tumor board at Gustave Roussy Institute in Villejuif, France. He is a member of ASCO, AACR, ESMO, and has been the chair of the GU Group of ESMO from 2008 to 2010, and is currently the ESMO faculty coordinator for the GU group. He has be leading the ESMO guidelines for kidney cancer in 2012 and 2014. Dr Escudier is also part of the steering committee of KCA, and has been in the scientific committee of the European kidney cancer symposium from the first meeting 8 years ago til now. Dr Escudier is also president of ARTuR, the French association for research for renal tumors. Dr Escudier is also leading the network CARARE, founded in 2013, devoted to rare kidney tumors in France. He has published more than 370 papers in peer reviewed journals, mainly in the field of Renal Cancer.
    • Medical Oncology
    • Renal Cell Carcinoma
    • Melanoma
    Leader, Kidney Cancer Program, Dana-Farber/Harvard Cancer Center, Director/Attending Biologic Therapy and Cutaneous Oncology Programs, Hematology/Oncology, Beth Israel Deaconess Medical Center
    Leader, Kidney Cancer Program, Dana-Farber/Harvard Cancer Center, Director/Attending Biologic Therapy and Cutaneous Oncology...
    Dr. David McDermott is Director of the Biologic Therapy and Cutaneous Oncology Programs at Beth Israel Deaconess Medical Center treating patients with renal cell carcinoma and melanoma. Leader of the Dana Farber/Harvard Cancer Center (DF/HCC) Kidney Cancer Program and co-Principal Investigator of the National Cancer Institute Kidney Cancer SPORE Grant at the DF/HCC. Dr. McDermott is a medical oncologist and clinical investigator with a particular interest in therapies that enhance the immune response to cancer. He has contributed to the rational application of interleukin-2 and immune check point inhibitors (CTLA-4, PD-1 antibodies) for renal cell carcinoma and melanoma and worked with anti-angiogenic agents and targeted therapeutics for these malignancies. He is Director of the Cytokine Working Group a major innovator in the field of solid tumor immunotherapy and Associate Professor of Medicine at Harvard Medical School. Dr. McDermott earned his medical degree from Cornell University Medical College and completed his residency in internal medicine and fellowship in Hematology/Oncology at Tufts/New England Medical Center. He has served on the Program Committee for the American Society of Clinical Oncology, the Medical Advisory Board for the Kidney Cancer Association, the NCI GU Steering Committee and currently serves on the Kidney Cancer Task Force. Dr. McDermott is a clinical expert on the treatment of renal cell carcinoma and melanoma and a nationally and internationally recognized investigator and teacher.
  • Dr. Saby George is a board certified Medical oncologist who has a passion for Genitourinary Oncology research. He has been working at the prestigious Roswell Park Cancer Institute since 2010. He has been providing high quality patient care with a multi-disciplinary team approach. Dr. George is an active faculty member at Roswell Park Cancer Institute and mentors oncology fellows. His main academic focus is clinical research in kidney, bladder and prostate cancer. Dr. George has been the site principle investigator of many clinical trials and works with the leaders in the field at the national level. In addition to clinical trials, his interest in kidney cancer also includes metabolism of kidney cancer cell, improving the response evaluation criteria particularly related to targeted therapies/ immuno-oncology agents, and the mechanism of resistance formation to tyrosine kinase inhibitors. Dr. George is an active member of Alliance for Clinical Trials in Oncology and American Society of Clinical Oncology (ASCO). He has many first-author original manuscripts and is passionate to change the natural history of kidney cancer.
    • Medical Oncology
    • Assistant Professor of Oncology at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
    I am an Assistant Professor of Oncology and a medical oncologist at Johns Hopkins with a focus on GU malignancies, in particular kidney cancer. I have been involved in the clinical development of nivolumab mono- and combination therapies in kidney cancer from the phase I to phase III.
    • Medical Oncology
    • Renal Cell Carcinoma
    • Professor of Medical Oncology at Swansea University
    Professor Wagstaff is a Medical Oncologist at The College of Medicine, Swansea University having trained at the Christie Hospital in Manchester, and has has co-authored over 127 papers in International Peer reviewed journals. He is also a Professor of Medical Oncology within the College of Medicine at Swansea University, a Director of the Wales Cancer Research Network and Deputy Director of the Wales National Institute for Social Care and Health Research Clinical research Centre (NISCHR-CRC). One of Professor Wagstaff’s main focuses is developing clinical trials for patients, whilst conducting translational research to better understand the effects of new treatments on patients with cancer.
    • Medical Oncology
    • Associate Director for Translational Research at UC Davis Comprehensive Cancer Center
    Primo “Lucky” Lara, Jr., MD, is Professor of Medicine at the University of California (UC) Davis School of Medicine and Associate Director for Translational Research at the UC Davis Comprehensive Cancer Center. His principal research and clinical interests revolve around developmental therapeutics in solid tumor oncology, particularly genitourinary (GU) and thoracic malignancies. He has been on the faculty of UC Davis since 1999. He is chair of the Southwest Oncology Group’s (SWOG) Advanced Renal Cell Cancer Organ Site since 2002. He is currently receiving research funding as Principal Investigator (PI) of several programs, including a National Cancer Institute (NCI) K12 Paul Calabresi Clinical Oncology Training Grant, N01 Early Therapeutics with Phase II Emphasis Award (California Cancer Consortium), and an American Cancer Society Institutional Research Grant, among others. He has also been PI on prior NCI-funded R21 and R01 grants. He serves as an active co-investigator on NCI-funded P30, UM1, and U10 drug development awards at UC Davis. He has successfully led numerous clinical trials, ranging from phase I to III, and has authored or co-authored over 215 peer-reviewed manuscripts, most notably on novel or emerging antineoplastic strategies in GU and lung cancers. He is proud to have mentored many junior faculty throughout his career. Dr. Lara currently serves as a permanent member of NCI’s Subcommittee F (Institutional Training and Education) Study Section, Member of the NCI’s Investigational Drug Steering Committee, and Chair of SWOG’s Professional Review Committee, among other commitments. He has contributed to the scientific program committees of the Society of Urologic Oncology and the IASLC, and was co-chair of the Kidney Cancer Committee (II) of the 2014 European Association of Urology-International Consultation on Urological Diseases. Dr. Lara has also been an active volunteer for the American Society of Clinical Oncology (ASCO), currently serving as an elected member of its Nominating Committee and having served for many years on the Cancer Education Committee, including as Chair of the Continuing Medical Education Subcommittee from 2012-2013 and as Genitourinary Cancer Track Leader from 2010-2011, among others. Dr. Lara has also served on the Journal of Clinical Oncology Editorial Board (2009-2012; 2012-2014) as well as faculty volunteer in many ASCO’s Annual Meetings and co-sponsored thematic symposia.
    • Medical Oncology
    • Renal Cell Carcinoma
    Director of The Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute
    Director of The Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute
    • Director, The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, Harvard Medical School

    Dr. Toni K. Choueiri is the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute/Brigham and Women’s Hospital and an Associate Professor of Medicine at Harvard Medical School. He is the Co-Leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center and President of the Medical Staff at Dana-Farber. He serves on the National Comprehensive Cancer Network (NCCN) Kidney Cancer Panel, the GU Steering Committee (GUSC) Task Force of the National Cancer Institute (NCI), and is Chairman of the Medical and Scientific Steering Committee of the Kidney Cancer Association. Dr. Choueiri is interested in developing novel therapies and biomarkers in GU malignancies. His research also focuses on epidemiology, diagnosis and treatment outcomes of prostate and urinary cancers using large scale approaches such as meta-analyses from available published trials or national databases. His work has been funded by the American Society of Clinical Oncology, the Harvard Kidney Cancer SPORE, the NCI, and Industry partners. He has over 400 PubMed-listed publications and is the overall principal investigator of multiple national and international phase I-III trials in GU cancers.

    • Medical Oncology
    • Head, Section of Genitourinary Medical Oncology at Keck School of Medicine, University of Southern California
    David Ian Quinn MBBS (Hons. I) PhD FRACP FACP undertook his early training at St. Vincent’s Hospital in Sydney before completing a PhD in Cancer Biology at the Garvan Institute and moving to the United States in 2000. Associate Professor Quinn is currently the Medical Director of the Norris Cancer Hospital and Clinics, Head, Section of Genitourinary Medical Oncology and Associate Professor of Medicine in the Division of Medical Oncology, Keck School of Medicine, University of Southern California. Prior experience includes Directorship of the Clinical Investigation Support Office and Leadership of the Genitourinary Cancer and Developmental Therapeutics Programs for the USC Norris Comprehensive Cancer Center. He is a medical oncologist with focus in the field of clinical trials and molecular correlative studies in genitourinary cancer and early therapeutics. David Quinn has published more than 150 papers, reviews and chapters including recent publications in New England Journal of Medicine, Lancet Oncology, Journal of the National Cancer Institute, Cell Stem Cells and Journal of Clinical Oncology. He is a reviewer for more than 50 peer-reviewed journals, is on the editorial boards of American Journal of Clinical Oncology, cancer.net (American Society of Clinical Oncology), Clinical Genitourinary Cancer, Bladder Cancer and Annals of Oncology and has been an invited speaker in more than 30 countries. Dr. Quinn is a member of the NCI Renal Cancer Task Force, Co-Chair for Genitourinary Cancer in the California Cancer Consortium and is SWOG organ site chair for advanced prostate cancer. His recent focus is on clinical trials and translation applications at USC and with SWOG and the California Cancer Consortium, where he has been principal investigator on more than 100 clinical trials for locally advanced and castrate-resistant prostate cancer, high grade urothelial cancer, advanced renal cell cancer, refractory germ cell tumors and adrenocortical carcinoma.